Evidence map›Paper›PMID 40967799›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Takotsubo Syndrome Following Combination Therapy with Dabrafenib and Trametinib.

Tatsuya Nishikawa, Shuichi Ohe, Yuta Suzuki, Masaya Kobayashi, Soichiro Tateishi, Yasuhiko Yamane, Shota Bun, Rika Sakamoto, Yu Kurokami, Hironori Yamamoto and 2 more

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tatsuya NishikawaDepartment of Onco-cardiology, Osaka International Cancer Institute, Japan.
Shuichi OheDepartment of Dermatologic Oncology, Osaka International Cancer Institute, Japan.
Yuta SuzukiDepartment of Radiology, Osaka International Cancer Institute, Japan.
Masaya KobayashiDepartment of Radiology, Osaka International Cancer Institute, Japan.
Soichiro TateishiDepartment of Radiology, Osaka International Cancer Institute, Japan.
Yasuhiko YamaneDepartment of Radiology, Osaka International Cancer Institute, Japan.
Shota BunDepartment of Dermatologic Oncology, Osaka International Cancer Institute, Japan.
Rika SakamotoDepartment of Dermatologic Oncology, Osaka International Cancer Institute, Japan.
Yu KurokamiDepartment of Dermatologic Oncology, Osaka International Cancer Institute, Japan.
Hironori YamamotoDepartment of Onco-cardiology, Osaka International Cancer Institute, Japan.
Taku YasuiDepartment of Onco-cardiology, Osaka International Cancer Institute, Japan.
Masashi FujitaDepartment of Onco-cardiology, Osaka International Cancer Institute, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Takotsubo syndrome, a transient stress-induced cardiomyopathy characterized by left ventricular dysfunction, has previously been reported to be associated with several anticancer agents. We herein report a rare case of Takotsubo syndrome associated with dabrafenib/trametinib combination therapy. A 76-year-old man with malignant melanoma was treated with a dabrafenib/trametinib combination therapy. After six months of treatment, the patient developed symptomatic heart failure. Echocardiography, cardiac magnetic resonance imaging, and myocardial single-photon emission computed tomography were performed, leading to the diagnosis of Takotsubo syndrome. In the absence of any physical or emotional stressors, Takotsubo syndrome was deemed to have been induced by combination therapy.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsImidazolesOximesPyridonesPyrimidinonesTakotsubo CardiomyopathyAgedHumansMaleMelanomaSkin NeoplasmsdabrafenibImidazolesOximesPyridonesPyrimidinonestrametinibapical ballooningBRAF inhibitorcardiomyopathycardiovascular toxicityMEK inhibitor

Identifiers

PMID40967799
PMCPMC13175653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.